HUTCHMED presents Phase III anemia data following regulatory advancements in China
HUTCHMED (NASDAQ:HCM) reported detailed Phase III data for its investigational oral spleen tyrosine kinase (Syk) inhibitor, sovleplenib, at the European Hematology Association (EHA) 2026 Congress.
The findings from the registration portion of the ESLIM-02 trial demonstrate that the therapy achieved rapid and durable control of hemolysis in patients with warm antibody autoimmune hemolytic anemia (wAIHA), a chronically relapsing and potentially life-threatening rare blood disorder.
The randomized, double-blind, placebo-controlled trial evaluated 90 adult patients in China with primary or secondary wAIHA who had relapsed after or were refractory to at least one prior line of standard corticosteroid treatment.
The study successfully met its primary endpoint, with sovleplenib achieving a 66% durable hemoglobin response rate during weeks 5 through 24, compared to a 15% response rate in the placebo arm.
Secondary endpoints consistently favored the therapeutic candidate across the 24-week evaluation interval.
Treatment with sovleplenib resulted in an overall response rate of 70% versus 22% for placebo, while significantly lowering the reliance on protocol-defined rescue therapies and red blood cell transfusions.
Furthermore, half of the patients receiving the study drug successfully tapered or discontinued baseline glucocorticoid usage, compared to 15% of individuals on placebo.
The safety evaluation revealed a favorable and well-tolerated profile consistent with previous clinical stages, showing no new or unexpected safety signals.
Backed by the positive registration data, the company's New Drug Application (NDA) for sovleplenib has been formally accepted for review by China’s National Medical Products Administration (NMPA).
The regulatory body has granted the submission priority review status alongside an official Breakthrough Therapy Designation, accelerating the anticipated commercial timeline for a therapeutic area that currently lacks approved targeted therapies.
